Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06603597 · ClinicalTrials.gov registry record
HER2-positive Breast Cancer Registry
A clinical trial of HER2 + Breast Cancer, sponsored by Priyanka Sharma.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 6
- Study locations
NCT06603597: Recruiting study of HER2 + Breast Cancer, sponsored by Priyanka Sharma.
NCT06603597 is a study of HER2 + Breast Cancer that is actively recruiting participants, run by Priyanka Sharma. The registered enrollment target is 1,000 participants, above the 196-participant average among 8 other HER2 + Breast Cancer trials with a reported enrollment target (410% higher). The trial reports 6 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06603597, a study of HER2 + Breast Cancer, is actively recruiting participants, sponsored by Priyanka Sharma.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of this observational study is to better understand links between patient or tumor characteristics and outcomes in HER2-positive breast cancer.
Primary Outcome
For patients with stage I-III HER2-positive breast cancer, percentage of patients who are alive at 5 years after diagnosis.
Conditions Studied
Study Locations (6)
Kansas
- KUCC - Indian Creek - Overland Park
- KUCC - Overland Park - Overland Park
- KUCC - Briarcliff - Westwood
- KUCC - Olathe - Westwood
- The University of Kansas Cancer Center - Westwood
Missouri
- KUCC - Lee's Summit - Lee's Summit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2024-09-27 |
| Est. Completion | 2044-10 |
What NCT06603597 shows while recruiting
NCT06603597 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 196-participant average among 8 other HER2 + Breast Cancer trials with a reported enrollment target (410% higher).
The record links to 1 condition, with HER2 + Breast Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06603597 lists 6 locations in 2 states (Kansas, Missouri).
Frequently Asked Questions
What is clinical trial NCT06603597 about?
NCT06603597 is a clinical study titled "HER2-positive Breast Cancer Registry". The goal of this observational study is to better understand links between patient or tumor characteristics and outcomes in HER2-positive breast cancer.
What is the current status of trial NCT06603597?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2024-09-27. Estimated completion is 2044-10.
What conditions does trial NCT06603597 study?
This clinical trial studies the following conditions: HER2 + Breast Cancer.
Who is sponsoring clinical trial NCT06603597?
This trial is sponsored by Priyanka Sharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06603597 being conducted?
This trial has 6 study locations across Kansas, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2 + Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06603597's enrollment target sits among peer trials
1,000 1st of 8 higher than 8 of 8 other HER2 + Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HER2 + Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RECRUITING · Phase 1
-
A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer
RECRUITING · Phase 1
-
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
RECRUITING
-
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
RECRUITING · Phase 2
-
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
RECRUITING · Phase 2
-
Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response by Anti-HER2 Treatment (HER2 CR)
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI